Abstract: Complexes comprising a nucleic acid-guided endonuclease, a sequence-specific targeting nucleic acid and an amphipathic helical peptide are provided. Compositions and methods for delivery of complexes comprising a nucleic acid-guided endonuclease, a sequence-specific targeting nucleic acid and an amphipathic helical peptide to mammals for both research and therapeutic use are provided. Methods of treating or reducing one or more symptoms of type 2 diabetes, prediabetes and/or gestational diabetes are provided.

Abstract: Described herein are compounds of the formula (I), as well as pharmaceutical compositions comprising such compounds, and methods for using such compounds/pharmaceutical compositions for treating neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, Huntington's disease, and multiple sclerosis (MS).

Abstract: Various embodiments disclosed relate to a substrate. The present disclosure provides a substrate for use in both surface enhanced Raman spectroscopy and surface enhanced infrared spectroscopy. The substrate includes a flexible polymeric membrane, a plurality of metal oxide nanoparticles disposed on the polymeric membrane, and a plurality of metallic nanoparticles directly disposed on a portion of the plurality of metal oxide nanoparticles. The plurality of metal oxide nanoparticles are configured to work synergistically with metal nanoparticles upon exposure of the substrate surface to at least one of visible light or infrared radiation.

Abstract: The invention provides a novel class of MRI contrast agents based on biogenic hemin and compositions and methods of preparation and use thereof.

Abstract: In one aspect, the invention relates to a method of loading exosomes with oligonucleotide cargo, by incubating an oligonucleotide comprising one or more hydrophobic modifications with a population of exosomes for a period of time sufficient to allow loading of the exosomes with the oligonucleotide. Exosomes loaded with hydrophobically modified oligonucleotide cargo, and uses thereof, are also provided.

Abstract: Autonomous vehicle operational management may include traversing, by an autonomous vehicle, a vehicle transportation network. Traversing the vehicle transportation network may include operating a scenario-specific operational control evaluation module instance, wherein the scenario-specific operational control evaluation module instance is an instance of a scenario-specific operational control evaluation module, wherein the scenario-specific operational control evaluation module implements a partially observable Markov decision process. Traversing the vehicle transportation network may include receiving a candidate vehicle control action from the scenario-specific operational control evaluation module instance, and traversing a portion of the vehicle transportation network based on the candidate vehicle control action.

Abstract: Methods and phosphorus-containing solid catalysts for catalyzing dehydration of cyclic ethers (e.g., furans, such as 2,5-dimethylfuran) and alcohols (e.g., ethanol and isopropanol). The alcohols and cyclic ethers may be derived from biomass. One example includes a tandem Diels-Alder cycloaddition and dehydration of biomass-derived 2,5-dimethyl-furan and ethylene to renewable p-xylene. The phosphorus-containing solid catalysts are also active and selective for dehydration of alcohols to alkenes.

Abstract: Systems, devices, and methods for proportionally balancing power during wireless communication are provided. The disclosures provide for an integrated radio in which the functionality of an active radio and a passive radio are integrated into a single radio, with the active and passive radios each being configured to operate in three different modes: active, passive, and backscatter. Based on power and communication link information, the integrated rode is able to balance the modes at which the two radios are operated, thereby optimizing power consumption of the device into which the integrated radio is incorporated. The resulting systems, devices, and methods lead to ultra-low power consumption that enables these communication techniques to enhance computing devices from smartwatches to laptops. Devices incorporating the integrated radios, and methods for power-proportionally exchanging data, among other systems, devices, and methods, are also provided.

Abstract: Therapeutic oligonucleotides comprising pharmacokinetic (PK)-modifying anchors are provided. Methods for treating diseases or disorders comprising administering to a subject a therapeutic oligonucleotide comprising one or more PK-modifying anchors are provided.

Abstract: Compositions and methods for treating or reducing the severity or likelihood of occurrence of a parasitic worm or helminth infection in a subject are described. The methods include administering to the subject a therapeutically effective amount of a killed or inactivated recombinant bacterium expressing a crystal protein such as a Bacillus thuringiensis crystal protein (Cry) in the cytosol of the bacterium. The crystal proteins may be full length, truncated, variant, or sub-variant Cry proteins. Examples of crystal proteins include Cry5B, Cry21, Cry14A, Cry6A, and Cry13A. The recombinant bacteria may be treated with an anti-microbial agent before or during administration to a subject.

Abstract: Methods for treating or reducing the risk of a cytomegalovirus infection in a subject that include administering one or more of an inhibitor of Deleted in Malignant Brain Tumors 1 (DMBT1), an inhibitor of OR14I1, or an inhibitor of adenylyl cyclases.

Abstract: Methods of treating a tumor in a subject include identifying a subject having, at risk for, or suspected of having a tumor, and administering to the subject an effective amount of an SRPX.

Abstract: Aspects of the disclosure relate to compositions and methods for expressing one or more anti-Vascular endothelial cell growth factor (VEGF) agents in a cell or subject. In some embodiments, the disclosure provides isolated nucleic acids and rAAVs comprising a transgene encoding an anti-VEGF agent (e.g., KH902) and one or more regulatory sequences. In some embodiments, compositions described herein are useful for treating subjects having diseases associated with angiogenesis or aberrant VEGF activity/signaling.

Abstract: The disclosure relates, in some aspects, to adeno-associated vims capsid proteins isolated from an in vivo library and recombinant adeno-associated viruses (rAAVs) comprising the same. In some aspects, the disclosure relates to isolated nucleic acids encoding AAV capsid proteins isolated from an in vivo library. In some embodiments, rAAVs and compositions described by the disclosure are useful for delivery of one or more transgenes to the muscle-tissue of a subject.

Abstract: Systems, devices, and methods of the present application can accelerate and reduce medical complications associated with healing of non-planar wounds such as amputation wounds. The devices and methods utilize a collapsing structure and negative pressure to cause the shaped wound to preferentially close. The structure can accommodate movement over curved tissue surfaces, which can utilize scales or interleaved elements to provide efficient wound closure along arcuate paths. This structure can enable gradual closure from the deepest portion of the wound to the shallowest portion.

Abstract: A parallel plate lens including a top plate, a bottom plate, a side-wall coupled to the top plate and the bottom plate to form the parallel plate lens with a cavity, and a plurality of capacitive probe feeds disposed in the cavity at a spacing interval associated with a guided wavelength (?) within the cavity.

Abstract: The invention provides novel classes of HCV therapeutics that are orally available, safe and effective HCV NS3/4A protease inhibitors and are less susceptible to drug resistance than existing therapeutics. The invention also relates to pharmaceutical composition of these compounds and methods of preparation and use thereof.

Abstract: The instant disclosure provides RNA-modulating agents that function to recruit one or more small regulatory RNA molecules (e.g., miRNA molecules, Y RNAs, and siRNAs) to a target mRNA thereby modulating (e.g., inhibiting) the translation of the target mRNA or destabilizing the mRNA. Also provided are miRNA inhibitors and diagnostic agents that have improved binding affinity for their target miRNAs. Methods for using the RNA-modulating agents, miRNA inhibitors and diagnostic agents are also provided.

Abstract: Based at least in part on an understanding of the mechanisms by which small RNAs (e.g., naturally-occurring miRNAs) mediate RNA silencing in plants, rules have been established for determining, for example, the degree of complementarity required between an RNAi-mediating agent and its target, i.e., whether mismatches are tolerated, the number of mismatches tolerated, the effect of the position of the mismatches, etc. Such rules are useful, in particular, in the design of improved RNAi-mediating agents which allow for more exact control of the efficacy of RNA silencing.

Abstract: Methods and compositions for treating cancer, e.g., colorectal cancer, using a miR-101-3p inhibitor.